Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland

Détails

Ressource 1Télécharger: 25999239.pdf (836.36 [Ko])
Etat: Public
Version: Final published version
ID Serval
serval:BIB_0B8C497CD972
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
Périodique
Swiss Medical Weekly
Auteur(s)
Samaras P., Bargetzi M., Betticher D.C., Duchosal M.A., Heim D., Hess U., Ketterer N., Lerch E., Matthes T., Mey U., Pabst T., Taverna C., Zander T., Renner C.
ISSN
1424-3997 (Electronic)
ISSN-L
0036-7672
Statut éditorial
Publié
Date de publication
2015
Peer-reviewed
Oui
Volume
145
Pages
w14100
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review Publication Status: epublish
Résumé
The availability of drugs such as thalidomide, bortezomib and lenalidomide changed the landscape in myeloma treatment and has extended the median survival up to 10 years with a substantial improvement in quality of life. This development prompted a Swiss expert panel to re-evaluate the current status and formulate updated clinical recommendations for the diagnosis and treatment of plasma cell myeloma. These recommendations should help clinicians in their decision making to achieve the best outcome based on currently available data.
Mots-clé
Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Monoclonal Gammopathy of Undetermined Significance/pathology, Multiple Myeloma/diagnosis, Multiple Myeloma/therapy
Pubmed
Web of science
Open Access
Oui
Création de la notice
11/10/2016 16:29
Dernière modification de la notice
20/08/2019 13:33
Données d'usage